for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kissei Pharmaceutical Co Ltd

4547.T

Latest Trade

2,756.00JPY

Change

24.00(+0.88%)

Volume

63,600

Today's Range

2,750.00

 - 

2,800.00

52 Week Range

2,309.00

 - 

3,645.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,732.00
Open
2,782.00
Volume
63,600
3M AVG Volume
1.53
Today's High
2,800.00
Today's Low
2,750.00
52 Week High
3,645.00
52 Week Low
2,309.00
Shares Out (MIL)
46.72
Market Cap (MIL)
141,548.20
Forward P/E
37.53
Dividend (Yield %)
1.83

Next Event

Q2 2020 Kissei Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Kissei Pharmaceutical says marketing approval for "Beova® Tablets 50mg" for treatment of overactive bladder

Kissei Pharmaceutical says change of president

Kissei Pharmaceutical says rating withdrawal by R&I

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kissei Pharmaceutical Co Ltd

KISSEI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. Along with its subsidiaries, the Company operates in two business segments. The Medical Product segment is engaged in the manufacture and sale of medical pharmaceuticals, the collection and analysis of oversea medicines information, as well as the support for research and development. The Others segment is involved in the purchase and sale of materials, the design and development of systems, the processing of information, the construction of factories, research centers and offices, the maintenance and management of facilities, the manufacture and sale of noodle products, the provision of insurance agency services, the rental of information equipment, the sale of health supporting systems, as well as the restaurant business.

Industry

Biotechnology & Drugs

Contact Info

19-48, Yoshino

+81.263.259081

http://www.kissei.co.jp

Executive Leadership

Mutsuo Kanzawa

Chairman of the Board, Chief Executive Officer, Representative Director

Yoshio Furihata

President, Chief Operating Officer, Representative Director

Hiroe Sato

Vice President, Director

Keiji Fukushima

Managing Director, Chief Director of Pharmaceutical Sales

Yasuo Takehana

Managing Director, Director of Business Planning

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (JPY)

2017

158.740

2018

188.260

2019

117.330

2020(E)

72.800
Price To Earnings (TTM)
26.86
Price To Sales (TTM)
2.01
Price To Book (MRQ)
0.71
Price To Cash Flow (TTM)
19.10
Total Debt To Equity (MRQ)
2.05
LT Debt To Equity (MRQ)
1.07
Return on Investment (TTM)
2.45
Return on Equity (TTM)
2.28

Latest News

Latest News

BRIEF-Kissei Pharmaceutical says change of president

* Says it appoints Yoshio Furihata as president, to succeed Masaki Morozumi, effective June 27

BRIEF-Kissei Pharmaceutical completes share repurchase

* Says it completed repurchase of 1.6 million shares of its common stock, for 4.46 billion yen in total, through ToSTNeT-3, on Feb. 13

BRIEF-Kissei Pharmaceutical to repurchase up to 3.7 pct shares and retire treasury shares

* Says it will repurchase up to 1.8 million shares, representing 3.7 percent of outstanding, for up to 5.02 billion yen, through ToSTNeT-3, on Feb. 13

BRIEF-R&I affirms Kissei Pharmaceutical's rating at "A-" and says stable outlook - R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" - R&I

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up